| Objective:To detect the expression of EMA,EGP-2 and CK19 in peripheral bloods of breast cancer,and evaluate the diagnostic value of EMA,EGP-2 and CK19 being micro metastasis target of breast cancer.Methods:Adopt 6.0ml peripheral bloods of 65 patients with histological confirmed breast cancer and 37 patients with benign breast diseases,then separate to 3 tubes, Using EDTA as the anticoagulant,firstly,use liquid separation lymphocytes isolated mononuclear cells,adding EMA rabbit anti-human monoclonal antibody,EGP-2 mouse anti-human monoclonal antibody and CK19 mouse anti-human monoclonal antibody respectively,Flow cytometry was used to detect EMA,EGP-2 and CK19 positive cells(*10-5)in the peripheral bloods to show the tumor cells content, analyzing relationships between each of them and TNM stages,age,size of tumors, axillary lymph nodes metastasis and expression of estrogen receptor and progestin receptor as well and the significance of 3 indexes combined detection.Statistical methods:measurement data statistically significant difference t-test analysis.All statistics were performed using SPSS 10.0 software,complete with statistical significance(P＜0.05) Results:1,The expression rates of EMA,EGP-2 and CK19 in peripheral cells of breast cancer patients were higher than that of benign diseases patients,the differences among them have statistical significance(P＜0.05).the positive expression rates of EMA,EGP-2 and CK19 were 29.23%,24.62%和36.92%respectively,otherwise in normal controls the data were 8.10%,p value were 0.0126,0.0395和0.0015 respectively.2,In breast cancer groups,the expression levels of three tumor markers have no significant difference with patients age,expression of estrogen receptor and progestin receptor as well(P＞0.05).3,In breast cancer groups,the cases accompanying or not with axillary lymph node metastasis,the EMA expression rates(positive cells,*10-5)is 41.67%(10.52±6.68) and 13.79%(3.35±2.89)respectively,the EGP-2 expression rates(positive cells)is 36.11%(9.24±6.48)and 10.34%(2.61±1.82).the expression rates(positive cells *10-5) of EMA from stage 0 toⅣwere 11.11%(2.55±1.66),18.75%(4.38±2.98),26.32% (6.56±4.09),38.46%(8.24±5.51)and 62.50%(13.43±7.70)respectively,so as that to EGP-2 with 11.11%(2.14±1.40),12.50%(3.65±1.73),15.79%(5.04±4.33),38.46%(8.53±7.95)and 62.50%(15.34±5.81).The expression rates also have significant correlations with tumor sizes(P＜0.05).4,Each marker has a low accuracy to diagnose metastasis of breast tumor,the data is between 24.62%～36.92%.Combined detection increase the accuracy obviously,the accuracy rate of EMA+EGP-2 is 46.16%,EMA+CK19 is 50.77%,EGP-2+CK19 is 44.62%and EMA+EGP-2+CK19 can reach to 73.85%.It also indicate that although 2 markers combined detection could increase the accuracy rate to diagnose breast cancer,3 markers combined detection could obtain higher sensitivity and accuracy rates.The differences among them have statistical significance(P＜0.05).Conclusion:1,Compared with benign diseases groups,three tumor markers with epithelial sources all have over expression in peripheral bloods of breast cancer patients,indicating that clinical detection of their expression levels could be a adjunctive diadynamic criterias of breast cancer.2,Some peripheral bloods of breast cancer patients have metastases,the possibility were higher in cases with axillary lymph nodes metastasis and higher TNM stages, indicates that the expression rates of tumor markers maybe increase with breast tumor progress.3,Combined detection of EMA,EGP-2and CK19 can increase the diagnostic accuracy to breast cancer metastases.Detecting positive cells expression rates of 3 tumor markers in time may play an important role in the prognosis and treatment of breast cancer.
|
PDF Full Text Request